Pharmaceutical Technology, Aug 2, 2008 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe
Pharmaceutical Technology, Aug 2, 2008
Online Exclusive
Pharmaceutical Quality Systems
By Angie Drakulich
Myth versus Reality: What does Q10 implementation really mean for my company?
A Guide That Perplexes
By Roger Dabbah
Despite its flaws, a recent release fills a need for books about pharmaceutical project management.
Extractables and Leachables: An Overview of Emerging Challenges
By Poonam Kushwaha , A. K. Madan
Extractables and leachables are a growing concern for pharmaceutical manufacturers and regulatory bodies.
Special Report
All Roads Now Lead to Quality Systems
By Angie Drakulich
After five years in the making, the official pharmaceutical quality system is here. All three parties to ICH adopted a final version of Q10 and agreed to implement the guideline through their individual regulatory bodies.
Peer-Reviewed Research
An Alternative to the USP Disintegration Test for Orally Disintegrating Tablets
By Jae Han Park , Kevin M. Holman , Glenn A. Bish , Donald G. Krieger , Daniel S. Ramlose , Cliff J. Herman , Stephen H. Wu
The authors propose an alternative to the USP disintegration test method. The method embraces physiological conditions of the oral cavity, as a screening tool for developing ODT products.
Comparing Calibration Technologies for Liquid-Handling Quality Assurance
By Richard Curtis , George Rodrigues
The authors consider several common techniques for verifying the accuracy of liquid-handling equipment and offer guidance for finding the appropriate technique for a given instrument.
Ingredients Insider
CMOs Invest in High-Potency Manufacturing
By Patricia Van Arnum
CMOs expand capacity and capabilities in high-potency manufacturing to meet strong demand for cytotoxic and other potent drugs.
Packaging Forum
Saved by the Delay
By Hallie Forcinio
Postponement of California's deadline gives the supply chain time to refine ePedigree solutions.
Outsourcing Outlook
Clinical Outsourcing Steams Ahead
By Jim Miller
CMC service providers are doing well, but clinical and preclinical CROs are doing even better.
Washington Report
Sentinel to Transform Drug Development and Oversight
By Jill Wechsler
FDA is modernizing adverse-event reporting as part of a revolution in drug-safety assessment.
News
Report From: Vietnam
By Jane Wan
Surrounded by competition, Vietnam's 2020 vision focuses on building a biotech sector worthy of its Asian neighbors—as well as the growing global biopharmaceutical market
Agent-In-Place
Suspicious Times
By Control, a senior compliance officer
Agents report unusual chemistry, abnormal data analysis, and unconventional work practices.
Viewpoint
Can Big Pharma Produce the Next Generation of Medicines?
By John Patterson
Patent pressures, changing disease profiles, and higher costs force companies to fight for the top.
Inside USP
Inside USP: US Pharmacopeia Guideline for Pending Monographs
By Karen A. Russo , Roger L. Williams
USP's guideline for pending monographs can speed up publication of monograhs and time to market.
From The Editor
FDA and Medicare at Odds?
By Michelle Hoffman
Legislative decisions to increase Medicare's formulary may lead to a fight over drug approvals.
PharmTech Talk
Charting Advances at CRS
By Patricia Van Arnum
This year's meeting of the Controlled Release Society unveiled a plethora of research insights.
In the Spotlight
In the Spotlight
Editors' Picks of Pharmaceutical Science & Technology Innovations

ADVERTISEMENT
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
18%
To all process for new products only
14%
To select process for new products only
23%
To select processes for both new and legacy products
20%
Do not use QbD
25%
View Results
Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
FindPharma Custom Search
Featured Jobs

More Jobs
Click here